TILOMIDE

TILOMIDE (Dorzolamide, U.S.P. & Timolol, U.S.P.) Shaigan eye drops are a 5ml sterile ophthalmic solution. It is a beta-blocker & ophthalmic antiglaucoma agent used to lower intraocular pressure (IOP).

Package Contains: Each pack of Tilomide contains 5ml eye drops in a dropper bottle & a leaflet.

Composition: Each ml contains Dorzolamide (as HCI) U.S.P. 20mg.

Timolol (as Maleate), U.S.P. 5mg.

(Product Specs.: U.S.P).

Uses: Tilomide eye drops are used to lower increased intraocular pressure (IOP) in certain eye conditions. Specific indications include:

• Open-angle glaucoma is a chronic eye condition where fluid buildup increases pressure inside the eye, potentially damaging the optic nerve.
• Ocular hypertension (high eye pressure without optic nerve damage).
• Pseudoexfoliative glaucoma.

By combining dorzolamide and timolol, it acts to reduce the production of aqueous humor (the fluid inside the eye), thus lowering intraocular pressure.

Dosage & Administration: See package insert for full prescribing information or as directed by a registered doctor. The dose is one drop of TILOMIDE in the affected eye(s) two times daily. When substituting the drops for another ophthalmic antiglaucoma agent(s), discontinue the other agent(s) after proper dosing on one day, and start TILOMIDE on the next day. If another topical ophthalmic agent is being used, TILOMIDE and the other agent should be administered at least ten minutes apart.

Contraindications: TILOMIDE is contraindicated in patients with:

• bronchial asthma, or a history of bronchial asthma, or severe chronic obstructive pulmonary disease.
• sinus bradycardia, second or third degree atrioventricular block, overt cardiac failure, cardiogenic shock.
• hypersensitivity to any component of this product.

The above are based on the components and are not unique to the combination.

Precaution: Cardio-respiratory Reactions: As with other topically-applied ophthalmic agents, this drug may be absorbed systemically. The timolol component is a beta-blocker. Therefore, the same types of adverse reactions found with systemic administration of beta-blockers may occur with topical administration. Because of the timolol maleate component, cardiac failure should be adequately controlled before beginning therapy with TILOMIDE.

In patients with a history of severe cardiac disease, signs of cardiac failure should be watched for, and pulse rates should be checked. Respiratory reactions and cardiac reactions, including death due to bronchospasm in patients with asthma and rarely death in association with cardiac failure, have been reported following administration of timolol maleate ophthalmic solution.

Immunology and hypersensitivity: As with other topically applied ophthalmic agents, this drug may be absorbed systemically. The dorzolamide component is a sulfonamide. Therefore, the same types of adverse reactions found with systemic administration of sulfonamides may occur with topical administration. If signs of serious reactions or hypersensitivity occur, discontinue use of this preparation.

In clinical studies, local ocular adverse effects, primarily conjunctivitis and lid reactions, were reported with chronic administration of dorzolamide hydrochloride ophthalmic solution. Some of these reactions had the clinical appearance and course of an allergic-type reaction that resolved upon discontinuation of drug therapy. Similar reactions have been reported with TILOMIDE. If such reactions are observed, discontinuation of treatment with TILOMIDE should be considered.

Side Effects: In clinical studies, (Dorzolamide HCI & Timolol Maleate) was generally well tolerated; no adverse experiences peculiar to this combination drug have been observed.

Adverse experiences have been limited to those that were reported previously with dorzolamide hydrochloride and/or timolol maleate, in general, common adverse experiences were mild and did not cause discontinuation.

During clinical studies, 1035 patients were treated with (Dorzolamide HCI & Timolol Maleate). Approximately 2.4% of all patients discontinued therapy with (Dorzolamide HCI & Timolol Maleate) because of local ocular adverse reactions. Approximately 1.2% of all patients discontinued because of local adverse reactions suggestive of allergy or hypersensitivity.

The most frequently reported drug-related adverse effects were: ocular burning and stinging, taste perversion, corneal erosion, conjunctival injection, blurred vision, tearing, and ocular itching. Urolithiasis was reported rarely.

The following adverse reactions have been reported in post-marketing experience: dyspnea, respiratory failure, contact dermatitis, bradycardia, heart block, choroidal detachment following filtration surgery, and nausea.

Pregnancy: There are no adequate and well-controlled studies in pregnant women; TILOMIDE should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. It is not known whether dorzolamide hydrochloride is excreted in human milk (nursing mothers).

Timolol maleate does appear in human milk. Because of the potential for serious adverse reactions in the nursing infant, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Over dosage: No data are available with regard to human overdosage by accidental or deliberate ingestion of TILOMIDE.

There have been reports of inadvertent overdosage with timolol maleate ophthalmic solution with systemic effects similar to those seen with systemic beta-adrenergic blocking agents, such as dizziness, headache, shortness of breath, bradycardia, bronchospasm, and cardiac arrest. The most common signs and symptoms to be expected with overdosage of dorzolamide are electrolyte imbalance, development of an acidotic state, and possibly central nervous system effects.

Treatment should be symptomatic and supportive. Serum electrolyte levels (particularly potassium) and blood pH levels should be monitored. Studies have shown that Timolol does not dialyze readily.

Instructions: Protect from heat, light & moisture. Store at 15°C-25°C. To be used within 30 days after opening. Medicine should be kept out of the reach of children. To be sold on the prescription of a registered medical practitioner only. 

Manufactured & Buy Online:

Tilomide eye drops are manufactured by: Shaigan Pharmaceuticals (PVT) LTD.

This is the link to the manufacturer: https://shaigan

Buy Online: https://healthwire.pk

You can also buy it from any nearby pharmacy.